RecruitingPancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerColorectal Cancer
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
12 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Sponsor: Verastem, Inc.
Where it's recruiting
California
Los Angeles
Maryland
Baltimore
Massachusetts
Boston
Michigan
Ann Arbor
Missouri
St Louis
New York
New York
Pennsylvania
Philadelphia
Tennessee
Nashville
Texas
Houston
Utah
Salt Lake City
Virginia
Charlottesville · Fairfax
Washington
Seattle
Source: ClinicalTrials.gov · NCT07020221 · last updated 2026-04-22